ScalaMed, which went through the TMC Accelerator in 2018, has been acquired. Photo via TMC

Healthcare services giant Cardinal Health has acquired Houston-based startup ScalaMed, whose platform transfers prescriptions directly to patients via a secure mobile app. The purchase price wasn’t disclosed.

ScalaMed now falls under the umbrella of a Cardinal-owned company called Outcomes. ScalaMed’s technology will be available throughout Cardinal’s nationwide pharmacy network.

“As healthcare continues to evolve toward patient preferences, the acquisition of ScalaMed allows us to center our connected ecosystem around the patient from the outset of their treatment journey — from the doctor’s office to the pharmacy to home,” Brent Stutz, senior vice president and general manager of Dublin, Ohio-based Outcomes, says in a news release. “Using ScalaMed’s technology, we can better support patients at every step along their treatment journey through unified communication and more informed insights that will help remove access and adherence barriers.”

Dr. Tal Rapke, founder and CEO of ScalaMed, says the process of digitizing prescriptions removes the patient from the equation, helping them bypass challenges such as forgetting medication while on vacation or lacking a convenient pharmacy nearby.

ScalaMed, founded in 2016 in Australia, raised $1.1 million in funding, according to Crunchbase. It was a member of the TMC Accelerator’s medtech program in 2018.

“With the scale and innovation Cardinal Health offers, we can revolutionize how prescriptions are filled and help solve the massive, costly challenge of medication nonadherence,” says Rapke, who’s a physician.

According to an article published in 2016 by the Journal of Managed Care & Specialty Pharmacy, medication nonadherence happens when a new medication is prescribed for a patient, but the patient does not obtain the medication or an appropriate alternative within an “acceptable” period after it was prescribed.

An article published in 2018 by The Permanente Journal reported that medication nonadherence happens with as many as 40 percent to 50 percent of patients who are prescribed drugs for chronic conditions like diabetes and high blood pressure. Each year, medication nonadherence costs the U.S. healthcare system $528 billion and contributes to about 275,000 avoidable patient deaths, according to a study published in 2018 in the Annals of Pharmacotherapy.

“Medication adherence … constitutes one of the ‘big hairy problems’ or ‘big hairy audacious goals’ of healthcare,” says an editorial published in 2020 by BMJ Journals.

gBETA has announced its second Houston cohort. Photo courtesy of gBETA

Early-stage startup accelerator names latest Houston cohort

ready cohort 2

An early-stage startup accelerator with a national presence has announced its latest cohorts across the country. Five Houston companies have been named to the local class.

The accelerator, gBETA, is a part of Madison, Wisconsin-based gener8tor's suite of accelerators, and announced its plan to launch in Houston in September 2019. The program's inaugural cohort premiered in May and conducted the first program this summer completely virtually.

This week, gBETA named 50 startups across 10 cohorts to its fall program. Here are the five startups selected from Houston:

  • DOSS: Launched in April, DOSS uses artificial intelligence and data aggregation in the homebuying process.
  • Camelia Alise: The company creates gender-neutral skincare products to treat pseudo-folliculitis condition and has developed a specific spa curriculum for aspiring spa owners and specialists.
  • CaseCTRL: A management platform for surgeons, CaseCTRL's software-as-a-service technology uses AI and logistics to lower operational costs and simplify surgical planning.
  • Melanoid Exchange: An online platform, Melanoid Exchange is giving small minority businesses the opportunity to grow their business through eCommerce.
  • ScalaMed: The company has developed a smart prescriptions platform that provides care teams real-time information on their patients' drug management, and patients with an empowering tool that helps them take control over the prescription process.

The no-cost, equity-free program will last seven weeks and kicked off on October 1. While the program will continue to be virtual, gBETA's operations are located in Amegy Bank's Downtown Launchpad along with Impact Hub Houston and MassChallenge Texas.

"Over the past year, Central Houston has focused on establishing Downtown as a vibrant innovative center of gravity for technology and entrepreneurship in the northern node of the Houston Innovation Corridor," says Robert Pieroni, director of economic development at Central Houston, a gBETA Houston sponsor, in the news release.

"The result has been recruiting nationally-acclaimed accelerator programs, such as gener8tor, to our city and creating Downtown Launchpad, an inclusive village that offers a framework of resources for these programs and the startups and entrepreneurs involved as they seamlessly navigate through the stages of startup production. We're thrilled that gener8tor is one of Downtown Launchpad's resident partners and look forward to the impact created by the startups in the fall cohort."

gBETA Houston's Virtual Pitch Night will be held on Wednesday, Nov. 18, at 5 pm. For more information and to RSVP, click here.

gBETA kicked off its 2020 fall accelerator virtually. Photo courtesy of gBETA

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Greentown Houston announces plans for wet lab, calls for feedback from members

seeing green

Greentown Houston has announced it's building a new wet lab facility — but first, they need some help from the community.

Greentown Labs, which is dual located at their headquarters in Somerville, Massachusetts, and in the Ion District in Houston, has announced that they are building out a wet lab in their Midtown space.

"We have heard from several startups as well as corporate partners in the ecosystem that are looking for wet lab space," says Lara Cottingham, vice president of strategy, policy, and climate impact at Greentown Labs. "Greentown has experience running wet labs from our location in Somerville. We're excited to be able to offer wet lab space to climatetech startups as an additional amenity to the Ion District.

Although Greentown's Boston-area location has wet lab space, Cottingham says the organization is not interested in copying and pasting that same facility. Greentown wants to provide the tools that the Houston ecosystem needs, and that requires getting feedback from its current and potential members.

"We want to announce to the community that this is something we're going to build — but we still need a lot of feedback and input from startups so we can learn what exactly they need or want to see from the wet lab," Cottingham tells InnovationMap. "No two wet labs are the same."

Right now, there aren't any details available about timeline or specifics of the new facility. Greentown is prioritizing getting feedback from its members and having conversations with potential sponsors and corporate partners.

"Corporate partners are a big part of the ecosystem and the community at Greentown. They can be so many things to our startups — mentors, customers, investors," Cottingham says. "And in this space, they can help us sponsor and financially support the wet lab. We're still fundraising — we have some partners that have committed to funding, but we're still looking for more funding."

In addition to monetary contribution, Cottingham says they are looking for other options as well, from partnerships with equipment providers, hazardous materials management, and more.

Startups that need wet lab space are encouraged to fill out the online form, which will be open through the summer, and potential corporate partners can express their interest online as well.

Greentown Houston opened its doors in 2021 and has since grown to house more than 75 energy and climatetech startups, as well as several accelerators, thanks to support from dozens of corporate partners.

Recently acquired Houston hospitality tech company continues to expand following fresh funding

tech growth

Houston-based HungerRush, which is a point-of-sale system that includes payment-processing, digital ordering, customer engagement, and delivery management, continues to spread its impact to businesses big and small.

A New York private equity firm, Corsair Capital, saw the potential for the cloud-based POS software and purchased a majority stake in HungerRush last summer. In 2022, HungerRush was on target to reach $100 million in recurring revenue according to The Deal.

HungerRush aims to serve an industry that according to the tech company, 80 percent think technology is the way to go to assist restaurants with labor shortages and other barriers. HungerRush acquired artificial intelligence text ordering app OrderAI, ordering and marketing company 9Fold LLC and Menufy.com over the past two years to grow its reach.

In the first quarter, the company introduced a comprehensive all-in-one POS system bundle designed to meet the needs of independent operators (IOs), with the overall goal of providing a tech stack to transform the experiences of both restaurant staff and customers. Their partnership with Menufy, which helps IOs drive both growth and profitability through an online website and mobile app ordering experience and currently serves over 15,000 restaurants across the US market, has helped to deliver the transformed IO experience to pizza restaurants and our offerings have quickly expanded to serve Vietnamese and Mexican restaurants as well.

One of the businesses seeing the benefits of platforms like HungerRush is Little Pop’s Pizzeria, which is a Naperville, Illinois-based pizza spot that uses the HungerRush to communicate to help the small business keep up with the large demands of the Chicagoland suburbs.The app’s help has led to substantial business growth.

“Thanks to having 5,000 loyalty program customers stored in HungerRush, we were able to quickly communicate the new curbside pickup and no contact delivery options,” says HungerRush user Mike Nelson of Little Pop’s Pizzeria. “Getting the word out through email and Facebook has increased our business by 75 percent.”

HungerRush continues to flourish in a crowded marketspace, which Chief Revenue Officer Olivier Thierry attributes to the platform’s accessibility to the audience and variety of features.

“While speaking to small business restaurant owners, we continued to hear the unique challenges they faced around having to navigate multiple delivery app interfaces, labor scheduling solutions, and other tools – resulting in many ending the month under their goal quotas, “ Thierry says. “Our tech tools arm our IOs to be able to manage omnichannel ordering, inventory, loyalty programs, and labor scheduling - but most importantly, support them where they need it the most to be successful in today’s digital world.”

Expert: Houston has potential to be a major hub for life sciences — if it addresses these concerns

guest column

Once upon a time in Houston, a promising startup, let’s call it BioMatrix, set out to revolutionize the world of biomaterials. Their groundbreaking product held immense potential, but the company faced the harsh reality of a lack of funding, resources, and talent in their local life sciences sector.

As they watched well-funded competitors in established hubs like Boston and Silicon Valley flourish, the passionate team at BioMatrix persevered, determined to overcome these challenges, and make their mark in the rapidly evolving world of MedTech and life sciences. But would they ultimately move to a richer life science hub?

Over the years, Houston has emerged as a life sciences hub, fueled by the world's largest medical center, Texas Medical Center, and an expanding network of research institutions, startups, and investors. However, despite all its potential, the city still lags other innovation hubs and isn’t included in many of the lists for top life science ecosystems. The challenges are many-fold, but some primary challenges are associated with lack of capital, trouble with talent acquisition, and weak collaboration.

Despite an uptick in venture capital funding, Houston's life sciences sector still trails the likes of Silicon Valley and Boston. Programs like CPRIT help keep companies within Texas, while Houston's unique advantages, such as lower living costs and the TMC's presence, can attract investments, but ultimately, to secure necessary capital, stakeholders must cultivate relationships with investors, government agencies, and other funding sources to infuse more money into the Houston ecosystem. And, when individuals try to do this, the rest of the ecosystem must be supportive.

Talent retention and attraction pose another challenge, as Houston competes with well-funded life science hubs offering abundant research institutions and funding opportunities. While Houston boasts numerous educational institutions producing skilled life sciences graduates, many curricula primarily prepare students for academic rather than industry careers, creating a skills and knowledge gap.

Having a lot of experience in academia doesn’t often translate well into the industry, as is demonstrated by many startup founders who struggle to understand the various stakeholder requirements in bringing a life science product to market.

To bridge this, educational institutions should incorporate more industry-oriented courses and training programs, like Rice University’s GMI Program, that emphasize practical skills and real-world applications. Collaborating with local companies for internships, co-op placements, and hands-on experiences can expose students to industry practices and foster valuable connections.

For any life science company, navigating the intricate regulatory landscape is also a challenge, as missteps can be disastrous. However, it’s even more of a challenge when you lack the fundamentals knowledge of what is required and the skills to effectively engage with industry experts in the space.

To address this, Houston must provide more opportunities for companies to learn about regulatory complexities from experts. Workshops, accelerators, or dedicated graduate and undergraduate courses focusing on regulatory compliance and best practices can facilitate knowledge and experience exchange between regulatory experts and innovators.

The initial inception of M1 MedTech was the result of a personal experience with a company who didn’t understand the fundamentals for regulatory interactions and didn’t know how to appropriately engage with consultants, resulting in time and money wasted.

Enhancing collaboration among Houston's life science stakeholders — including academia, research institutions, healthcare providers, subject matter experts, innovators, and investors — is fundamental for growth. A robust and lively professional network can stimulate innovation and help emerging companies access essential resources.

To this end, Houston should organize more industry-specific events, workshops, and conferences, connecting key life science players and showcasing the city's commitment to innovation. These events can also offer networking opportunities with industry leaders, attracting and retaining top talent. We’ve seen some of this with the Texas Life Science Forum and now with the Ion's events, but we could afford to host a lot more.

Houston's life sciences sector holds immense growth potential, but addressing funding, talent recruitment, regulatory navigation, and collaboration challenges is needed for continued success. By tackling these issues and leveraging its unique strengths, Houston can establish itself as a significant player in the global life sciences arenas. If we wait too long, we won’t be able to truly establish the Third Coast because another player will come into the mix, and we’ll lose companies like BioMatrix to their golden shores.

------

Isabella Schmitt is the director of regulatory affairs at Proxima Clinical Research and principal at M1 MedTech.